HRP20140635T1 - Multiäśestice - Google Patents
Multiäśestice Download PDFInfo
- Publication number
- HRP20140635T1 HRP20140635T1 HRP20140635TT HRP20140635T HRP20140635T1 HR P20140635 T1 HRP20140635 T1 HR P20140635T1 HR P20140635T T HRP20140635T T HR P20140635TT HR P20140635 T HRP20140635 T HR P20140635T HR P20140635 T1 HRP20140635 T1 HR P20140635T1
- Authority
- HR
- Croatia
- Prior art keywords
- multiparticles
- oxycodone
- pharmaceutical form
- plasticizer
- lubricant
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Manufacturing Of Micro-Capsules (AREA)
Claims (33)
1. Multičestice kontroliranog oslobađanja, ekstrudirane iz taline, koje sadrže (a) oksikodon, (b) u vodi netopljivi amonijev metakrilat kopolimer, (c) plastifikator, (d) lubrikant i (e) modifikator propustljivosti vode, pri čemu je taj modifikator propustljivosti vode mikrokristalinična celuloza, kroskarmeloza natrij, krospovidon ili natrijev škrob glikolat.
2. Multičestice prema zahtjevu 1, gdje je oksikodon prisutan kao farmaceutski prihvatljiva sol.
3. Multičestice prema zahtjevu 2, gdje je oksikodon prisutan kao oksikodon hidroklorid.
4. Multičestice prema bilo kojem od zahtjeva 1 do 3, gdje se plastifikator izabire između cetilnog alkohola, stearil alkohola, cetostearil alkohola, sorbitola, saharoze, polietilen glikol visoke molekulske težine, dibutil sebacat, tributil citrat, trietil citrat, propilen glikol i polietilen glikol niske molekulske težine.
5. Multičestice prema zahtjevu 4, gdje je plastifikator stearil alkohol.
6. Multičestice prema zahtjevu 4, gdje je plastifikator polietilen glikol visoke molekulske težine.
7. Multičestice prema bilo kojem od zahtjeva 1 do 6, gdje se lubrikant izabire između gliceril behenata, talka i silicijevog dioksida.
8. Multičestice prema zahtjevu 7, gdje je lubrikant gliceril behenat.
9. Multičestice prema bilo kojem od zahtjeva 1 do 6, gdje je lubrikant stearinska kiselina ili sol stearat.
10. Multičestice prema bilo kojem od zahtjeva 1 do 9, gdje je modifikator propustljivosti vode mikrokristalinična celuloza.
11. Multičestice prema bilo kojem od zahtjeva 1 do 10, gdje su količine sastojaka od (a) do (e) dane u postotcima u sljedećoj tablici, na temelju ukupne težine pet sastojaka:
oksikodon kao hidroklorid 3 do 50
netopljivi amonijev metakrilat kopolimer 25 do 85
plastifikator 1 do 30
lubrikant 1 do 25
modifikator propustljivosti vode 1 do 40
12. Muitičestice prema zahtjevu 11, gdje su količine sastojaka od (a) do (e) dane u postotcima u sljedećoj tablici, na temelju ukupne težine pet sastojaka:
oksikodon kao hidroklorid 5 do 40
netopljivi amonijev metakrilat kopolimer 35 do 75
plastifikator 3 do 25
lubrikant 2 do 25
modifikator propustljivosti vode 1 do 30
13. Multičestice prema zahtjevu 11, gdje su količine sastojaka od (a) do (e) dane u postotcima u sljedećoj tablici, na temelju ukupne težine pet sastojaka:
oksikodon kao hidroklorid 7,5 do 35
netopljivi amonijev metakrilat kopolimer 50 do 65
plastifikator 5 do 15
lubrikant 2 do 25
modifikator propustljivosti vode 1 do 20
14. Farmaceutski oblik u pojedinačnom dozirnom obliku koji sadrži multičestice prema bilo kojem od prethodnih zahtjeva.
15. Farmaceutski oblik prema zahtjevu 14, gdje pojedinačna doza daje dozu oksikodona koja je dovoljna za analgetski učinak u ljudskog bolesnika.
16. Farmaceutski oblik prema zahtjevu 15 koji je bioekvivalentan OxyContin® tabletama.
17. Farmaceutski oblik prema zahtjevu 15 ili 16, gdje je dovoljna doza oksikodona 5 do 400 mg.
18. Farmaceutski oblik prema zahtjevu 17, gdje je pojedinačna doza oksikodona 5 mg, 10 mg, 20 mg, 40 mg, 80 mg ili 160 mg.
19. Farmaceutski oblik prema bilo kojem od zahtjeva 14 do 18 u obliku kapsule napunjene tim multičesticama.
20. Farmaceutski oblik prema zahtjevu 19, gdje se multičestice pune u tvrde želatinske kapsule od kojih svaka sadrži pojedinačnu dozu.
21. Farmaceutski oblik prema zahtjevu 20, gdje je napunjena težina u kapsuli u rasponu 120 do 500 mg.
22. Farmaceutski oblik prema bilo kojem od zahtjeva 14 do 21, namijenjen primjeni u intervalima od 12 sati.
23. Farmaceutski oblik prema bilo kojem od zahtjeva 14, 15 i 17 do 21, namijenjen primjeni u intervalima od 24 sata.
24. Farmaceutski oblik koji sadrži multičestice prema bilo kojem od zahtjeva 1 do 13 i multičestice antagonista oksikodona.
25. Postupak pripreme multičestica prema zahtjevu 1 koji obuhvaća pripremu smjese koja sadrži (a) oksikodon, (b) u vodi netopljivi amonijev metakrilat kopolimer, (c) plastifikator, (d) lubrikant i (e) modifikator propustljivosti vode, pri čemu je taj modifikator propustljivosti vode mikrokristalinična celuloza, kroskarmeloza natrij, krospovidon ili natrijev škrob glikolat; te ekstruziju smjese.
26. Oblik prema bilo kojem od zahtjeva 14 do 24 za uporabu u medicini.
27. Oblik prema bilo kojem od zahtjeva 14 do 24 za uporabu za ublažavanje bolova.
28. Oblik prema bilo kojem od zahtjeva 14 do 24 za dobivanje analgetskog učinka.
29. Multičestice prema bilo kojem od zahtjeva 1 do 13 za uporabu u medicini.
30. Multičestice prema bilo kojem od zahtjeva 1 do 13 za uporabu za ublažavanje bolova.
31. Multičestice prema bilo kojem od zahtjeva 1 do 13 za dobivanje analgetskog učinka.
32. Uporaba multičestica prema bilo kojem od zahtjeva 1 do 13 u pripremi oblika za uporabu za ublažavanje bolova.
33. Uporaba multičestica prema bilo kojem od zahtjeva 1 do 13 u pripremi oblika koji ima analgetski učinak.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0315137A GB0315137D0 (en) | 2003-06-27 | 2003-06-27 | Multiparticulates |
| GB0403102A GB0403102D0 (en) | 2004-02-12 | 2004-02-12 | Multiparticulates |
| GB0413454A GB0413454D0 (en) | 2004-06-16 | 2004-06-16 | Multiparticulates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20140635T1 true HRP20140635T1 (hr) | 2014-09-26 |
Family
ID=33556051
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100127T HRP20100127T1 (hr) | 2003-06-27 | 2004-06-23 | Višečestični oblici |
| HRP20140635TT HRP20140635T1 (hr) | 2003-06-27 | 2014-07-04 | Multiäśestice |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100127T HRP20100127T1 (hr) | 2003-06-27 | 2004-06-23 | Višečestični oblici |
Country Status (25)
| Country | Link |
|---|---|
| EP (2) | EP1644002B1 (hr) |
| JP (2) | JP5348841B2 (hr) |
| KR (1) | KR101116518B1 (hr) |
| AR (1) | AR044935A1 (hr) |
| AT (1) | ATE453394T1 (hr) |
| AU (1) | AU2004251481B2 (hr) |
| BR (1) | BRPI0411901B1 (hr) |
| CA (1) | CA2530385C (hr) |
| CY (2) | CY1109917T1 (hr) |
| DE (1) | DE602004024888D1 (hr) |
| DK (2) | DK1644002T3 (hr) |
| EA (1) | EA013424B1 (hr) |
| ES (2) | ES2490598T3 (hr) |
| HR (2) | HRP20100127T1 (hr) |
| IL (1) | IL172730A (hr) |
| MX (1) | MXPA05013799A (hr) |
| MY (1) | MY176831A (hr) |
| NO (1) | NO20060443L (hr) |
| NZ (1) | NZ544181A (hr) |
| PE (1) | PE20050286A1 (hr) |
| PL (2) | PL1889621T3 (hr) |
| PT (2) | PT1889621E (hr) |
| SI (2) | SI1889621T1 (hr) |
| TW (1) | TWI357815B (hr) |
| WO (1) | WO2005000310A1 (hr) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6375957B1 (en) | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
| ES2412409T3 (es) | 1997-12-22 | 2013-07-11 | Euro-Celtique S.A. | Forma farmacéutica para dosificación oral que comprende una combinación de un agonista opiáceo y un antagonista opiáceo |
| EP1387673B1 (en) | 2001-05-11 | 2010-12-29 | Endo Pharmaceuticals Inc. | Abuse-resistant controlled-release opioid dosage form |
| EP1429744A1 (en) | 2001-09-21 | 2004-06-23 | Egalet A/S | Morphine polymer release system |
| EP2957281A1 (en) | 2001-09-21 | 2015-12-23 | Egalet Ltd. | Polymer release system |
| HUE031668T2 (en) | 2002-04-05 | 2017-07-28 | Euro Celtique Sa | Pharmaceutical composition containing oxycodone and naloxone |
| WO2004084868A1 (en) | 2003-03-26 | 2004-10-07 | Egalet A/S | Morphine controlled release system |
| TWI357815B (en) * | 2003-06-27 | 2012-02-11 | Euro Celtique Sa | Multiparticulates |
| GB0403098D0 (en) * | 2004-02-12 | 2004-03-17 | Euro Celtique Sa | Extrusion |
| TWI350762B (en) * | 2004-02-12 | 2011-10-21 | Euro Celtique Sa | Particulates |
| EP1604666A1 (en) | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD) |
| GB2418854B (en) | 2004-08-31 | 2009-12-23 | Euro Celtique Sa | Multiparticulates |
| EP2289491A1 (en) * | 2005-01-28 | 2011-03-02 | Euro-Celtique S.A. | Alcohol resistant dosage forms |
| EP1702558A1 (en) | 2005-02-28 | 2006-09-20 | Euro-Celtique S.A. | Method and device for the assessment of bowel function |
| US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
| BRPI0706753A2 (pt) * | 2006-01-21 | 2011-04-05 | Abbott Gmbh & Co Kg | forma de dosagem e método para a distribuição de fármacos de abuso |
| SA07280459B1 (ar) | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني |
| DE602008002073D1 (de) * | 2007-03-02 | 2010-09-16 | Farnam Co Inc | Wachsähnliches material enthaltende tabletten mit verzögerter freisetzung |
| MX337286B (es) | 2007-05-25 | 2016-02-22 | Indivior Uk Ltd | Formulaciones de transferencia sostenida de compuestos de risperidona. |
| CA2687192C (en) | 2007-06-04 | 2015-11-24 | Egalet A/S | Controlled release pharmaceutical compositions for prolonged effect |
| SI2180882T1 (sl) | 2007-10-19 | 2013-05-31 | Otsuka Pharmaceutical Co., Ltd. | Trdni matriksni farmacevtski pripravek |
| US9226907B2 (en) | 2008-02-01 | 2016-01-05 | Abbvie Inc. | Extended release hydrocodone acetaminophen and related methods and uses thereof |
| WO2010032128A1 (en) * | 2008-09-18 | 2010-03-25 | Purdue Pharma L.P. | Pharmaceutical dosage forms comprising poly(e-caprolactone) |
| AU2010211220B2 (en) | 2009-02-06 | 2013-08-01 | Egalet Ltd. | Immediate release composition resistant to abuse by intake of alcohol |
| DK2405915T3 (en) | 2009-03-10 | 2019-02-11 | Euro Celtique Sa | PHARMACEUTICAL COMPOSITIONS WITH IMMEDIATE RELEASE INCLUDING OXYCODON AND NALOXON |
| CA2766179A1 (en) | 2009-06-24 | 2010-12-29 | Egalet Ltd. | Controlled release formulations |
| EP2534479A1 (en) * | 2010-02-11 | 2012-12-19 | Harry Leider | Methods of normalizing measured drug concentrations and testing for non-compliance with a drug treatment regimen |
| US9272044B2 (en) | 2010-06-08 | 2016-03-01 | Indivior Uk Limited | Injectable flowable composition buprenorphine |
| GB2513060B (en) | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
| JP2015521988A (ja) | 2012-07-06 | 2015-08-03 | イガレット・リミテッド | 制御放出用乱用防止性医薬組成物 |
| WO2015011189A1 (en) | 2013-07-23 | 2015-01-29 | Euro-Celtique S.A. | A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation |
| CA3042642A1 (en) | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| WO2015095391A1 (en) | 2013-12-17 | 2015-06-25 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| GB201404139D0 (en) | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
| ES2809458T3 (es) | 2014-07-17 | 2021-03-04 | Pharmaceutical Manufacturing Res Services Inc | Forma de dosificación llena de líquido, disuasoria del abuso y de liberación inmediata |
| US9132096B1 (en) | 2014-09-12 | 2015-09-15 | Alkermes Pharma Ireland Limited | Abuse resistant pharmaceutical compositions |
| JP2017531026A (ja) | 2014-10-20 | 2017-10-19 | ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド | 徐放性乱用抑止性液体充填剤形 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4861598A (en) * | 1986-07-18 | 1989-08-29 | Euroceltique, S.A. | Controlled release bases for pharmaceuticals |
| JPH11508224A (ja) * | 1990-08-09 | 1999-07-21 | エンドコン・インコーポレーテッド | 多重ドラッグデリバリーシステム |
| US5266331A (en) * | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
| US5286493A (en) * | 1992-01-27 | 1994-02-15 | Euroceltique, S.A. | Stabilized controlled release formulations having acrylic polymer coating |
| CA2182282C (en) * | 1994-02-16 | 2006-04-18 | Jacqueline E. Briskin | Process for preparing fine particle pharmaceutical formulations |
| US5965161A (en) * | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
| WO1996034634A1 (en) * | 1995-05-01 | 1996-11-07 | Sam Yang Co. Ltd. | Implantable bioresorbable membrane and method for the preparation thereof |
| SE505146C2 (sv) * | 1995-10-19 | 1997-06-30 | Biogram Ab | Partiklar för fördröjd frisättning |
| AU3404997A (en) * | 1996-05-31 | 1998-01-05 | Euro-Celtique S.A. | Sustained release oxycodone formulations with no fed/fast effect |
| US6022554A (en) * | 1997-12-15 | 2000-02-08 | American Home Products Corporation | Polymeric microporous film coated subcutaneous implant |
| IT1304152B1 (it) * | 1998-12-10 | 2001-03-08 | Mediolanum Farmaceutici Srl | Composizioni comprendenti un peptide ed acido polilattico-glicolicoatte alla preparazione di impianti sottocutanei aventi un prolungato |
| FR2795326B1 (fr) * | 1999-06-28 | 2001-08-31 | Adir | Composition pharmaceutique solide thermoformable a liberation controlee |
| MXPA02004293A (es) * | 1999-10-29 | 2002-10-31 | Euro Celtique Sa | Formulaciones de hidrocodona de liberacion controlada.. |
| EP2092936B1 (en) * | 2000-02-08 | 2013-03-20 | Euro-Celtique S.A. | Tamper-resistant oral opioid agonist formulations |
| FR2818552B1 (fr) * | 2000-12-26 | 2003-02-07 | Servier Lab | Compositions pharmaceutique solide thermoformable pour la liberation controlee d'ivabradine |
| BR0309844A (pt) * | 2002-05-07 | 2005-02-15 | Control Delivery Sys Inc | Processos para formação de um dispositivo para a distribuição de droga |
| MXPA05007717A (es) * | 2003-01-24 | 2005-09-30 | Control Delivery Sys Inc | Liberacion controlada de agentes altamente solubles. |
| TWI357815B (en) * | 2003-06-27 | 2012-02-11 | Euro Celtique Sa | Multiparticulates |
-
2004
- 2004-06-18 TW TW093117618A patent/TWI357815B/zh not_active IP Right Cessation
- 2004-06-23 ES ES07013702.1T patent/ES2490598T3/es not_active Expired - Lifetime
- 2004-06-23 HR HR20100127T patent/HRP20100127T1/hr unknown
- 2004-06-23 PT PT70137021T patent/PT1889621E/pt unknown
- 2004-06-23 EA EA200600111A patent/EA013424B1/ru not_active IP Right Cessation
- 2004-06-23 SI SI200432174T patent/SI1889621T1/sl unknown
- 2004-06-23 CA CA2530385A patent/CA2530385C/en not_active Expired - Fee Related
- 2004-06-23 PL PL07013702T patent/PL1889621T3/pl unknown
- 2004-06-23 ES ES04743056T patent/ES2337468T3/es not_active Expired - Lifetime
- 2004-06-23 MX MXPA05013799A patent/MXPA05013799A/es active IP Right Grant
- 2004-06-23 JP JP2006516468A patent/JP5348841B2/ja not_active Expired - Fee Related
- 2004-06-23 SI SI200431330T patent/SI1644002T1/sl unknown
- 2004-06-23 EP EP04743056A patent/EP1644002B1/en not_active Expired - Lifetime
- 2004-06-23 DK DK04743056.6T patent/DK1644002T3/da active
- 2004-06-23 AT AT04743056T patent/ATE453394T1/de active
- 2004-06-23 KR KR1020057024940A patent/KR101116518B1/ko not_active Expired - Fee Related
- 2004-06-23 EP EP07013702.1A patent/EP1889621B1/en not_active Expired - Lifetime
- 2004-06-23 WO PCT/GB2004/002705 patent/WO2005000310A1/en active Application Filing
- 2004-06-23 AU AU2004251481A patent/AU2004251481B2/en not_active Ceased
- 2004-06-23 PL PL04743056T patent/PL1644002T3/pl unknown
- 2004-06-23 DE DE602004024888T patent/DE602004024888D1/de not_active Expired - Lifetime
- 2004-06-23 NZ NZ544181A patent/NZ544181A/en not_active IP Right Cessation
- 2004-06-23 DK DK07013702.1T patent/DK1889621T3/da active
- 2004-06-23 BR BRPI0411901-0A patent/BRPI0411901B1/pt not_active IP Right Cessation
- 2004-06-23 PT PT04743056T patent/PT1644002E/pt unknown
- 2004-06-24 PE PE2004000617A patent/PE20050286A1/es not_active Application Discontinuation
- 2004-06-25 AR ARP040102264A patent/AR044935A1/es not_active Application Discontinuation
- 2004-06-25 MY MYPI20042516A patent/MY176831A/en unknown
-
2005
- 2005-12-21 IL IL172730A patent/IL172730A/en active IP Right Grant
-
2006
- 2006-01-27 NO NO20060443A patent/NO20060443L/no not_active IP Right Cessation
-
2010
- 2010-03-19 CY CY20101100259T patent/CY1109917T1/el unknown
-
2013
- 2013-05-08 JP JP2013098685A patent/JP5960089B2/ja not_active Expired - Fee Related
-
2014
- 2014-07-04 HR HRP20140635TT patent/HRP20140635T1/hr unknown
- 2014-07-31 CY CY20141100577T patent/CY1115415T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20140635T1 (hr) | Multiäśestice | |
| RU2404750C2 (ru) | Композиция, содержащая основу или покрытие для замедленного высвобождения и антагонист nmda рецептора, способ введения такого nmda антагониста субъекту | |
| ES2205454T3 (es) | Formulaciones de claritromicina de liberacion prolongada. | |
| DK200000364U3 (da) | Oxycodenpræparater med kontrolleret afgivelse | |
| ES2635733T3 (es) | Uso de antagonistas opioideos para tratar la retención urinaria | |
| RU2008151950A (ru) | Фармацевтическая лекарственная форма пролонгированного высвобождения, содержащая фенилэфрин | |
| KR100699958B1 (ko) | 테르비나핀을 포함하는 제약학적 조성물 및 그의 용도 | |
| ES2865278T3 (es) | Amantadina para mejorar la marcha en esclerosis múltiple | |
| ES2409069A2 (es) | Uso de aglutinantes para fabricar formulaciones estables al almacenamiento | |
| US9387166B2 (en) | Controlled release oral dosage form comprising oxycodone | |
| AU2008303525B2 (en) | Use of a combination of an opioid agonist and an opioid antagonist for the treatment of Crohn's disease and the symptoms associated with Crohn's disease | |
| ES2408343A2 (es) | Composiciones farmacéuticas que comprenden hidromorfona y naloxona | |
| WO2007120485A2 (en) | Methods of treating pain with alkylxanthines and antiepileptics and compositions for use therefor | |
| WO2011146611A1 (en) | Modified gastroretentive drug delivery system for amine drugs | |
| US20100256088A1 (en) | Low dose therapy for treating viral infections | |
| GB2281205A (en) | Oral opioid analgesic | |
| AU2021204247A1 (en) | Pharmaceutical matrix formulations comprising dimethyl fumarate | |
| BR112014013374B1 (pt) | Comprimidos de acamprosato e usos de acamprosato referência cruzada aos pedidos relacionados | |
| JP2008247822A (ja) | 鎮痛用組成物 | |
| KR20160030093A (ko) | 구강 내 붕괴정 | |
| JP7523879B2 (ja) | 医薬組成物 | |
| JP2017171626A (ja) | プロピオン酸系非ステロイド性消炎鎮痛薬を含有した医薬組成物 | |
| JP2006001920A (ja) | 医薬製剤 | |
| BRPI0713601A2 (pt) | composição farmacêutica oral de alta dose de artemether e lumefantrina, processo para obtenção da mesma, uso da mesma e tablete divisìvel de artemether e lumefantrina | |
| JP2021075530A (ja) | 医薬組成物 |